About LumiThera
LumiThera is a company based in Poulsbo (United States) founded in 2013 by James Carroll, Luis De Taboada, Graham Merry, and Clark E Tedford was acquired by Alcon in September 2025. LumiThera has raised $35.33 million across 16 funding rounds from investors including Alcon, Nikon and NIH. The company has 18 employees as of December 31, 2022. LumiThera has completed 1 acquisition, including Diopsys. LumiThera offers products and services including Valeda Light Delivery System.
- Headquarter Poulsbo, United States
- Employees 18 as on 31 Dec, 2022
- Founders James Carroll, Luis De Taboada, Graham Merry, Clark E Tedford
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lumithera, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$35.33 M (USD)
in 16 rounds
-
Latest Funding Round
$10 M (USD), Series D
May 08, 2024
-
Investors
Alcon
& 12 more
-
Employee Count
18
as on Dec 31, 2022
- Investments & Acquisitions
-
Acquired by
Alcon
(Sep 05, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of LumiThera
LumiThera offers a comprehensive portfolio of products and services, including Valeda Light Delivery System.
Device for treating dry AMD by improving visual acuity through photobiomodulation.
People of LumiThera
Unlock access to complete
Unlock access to complete
Funding Insights of LumiThera
LumiThera has successfully raised a total of $35.33M across 16 strategic funding rounds. The most recent funding activity was a Series D round of $10 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in LumiThera
LumiThera has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Alcon, Nikon and NIH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are managed in the United States.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for LumiThera
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by LumiThera
LumiThera has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Diopsys.
Investment portfolio details for LumiThera
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Non-invasive visual electrophysiology devices are supplied for ophthalmological diagnosis.
|
Locked | Locked | 2002 | Locked |
Complete acquisition details for LumiThera
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - LumiThera
Detailed financials for LumiThera
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lumithera Comparisons
Peer comparison for LumiThera
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of LumiThera
Detailed competitors of LumiThera
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lumithera
Complete news archive for LumiThera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about LumiThera
LumiThera was founded in 2013.
LumiThera is headquartered in Poulsbo, United States. It is registered at Poulsbo, Washington, United States.
Clark E Tedford is the current CEO of LumiThera. They have also founded this company.
LumiThera is a funded company, having raised a total of $35.33M across 16 funding rounds to date.
As of Dec 31, 2022, the latest employee count at LumiThera is 18.
Founded in 2013 and headquartered in Poulsbo, United States, the company operates in the medical device sector. Photobiomodulation therapies for ocular conditions, including dry age-related macular degeneration, are developed through devices such as the Valeda light delivery system. LED and laser technologies are utilized in these non-invasive treatments to address various eye diseases. Operations focus on research, device manufacturing, and clinical applications in ophthalmology.
LumiThera offers Valeda Light Delivery System.
LumiThera has made 1 acquisition, including Diopsys.
LumiThera has 13 investors. Key investors include Alcon, Nikon, NIH, HHS, and Keiretsu Forum.